Balcom Alexandra 4

What Happened

• Alexandra Balcom, Chief Financial Officer of Nuvalent, exercised a total of 11,430 optioned shares (5,384 at $6.89 and 6,046 at $18.93) for a combined cost of $151,547, and on July 1, 2026 sold those 11,430 common shares in the open market at a weighted-average price of $123.58 for proceeds of $1,412,519. The filings also show the derivative instruments were converted/disposed in the exercise process.

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 6, 2026 (meets the two-business-day deadline; July 3 was a federal holiday observed).
• Option exercises: 5,384 shares @ $6.89 = $37,096; 6,046 shares @ $18.93 = $114,451; total cost ≈ $151,547.
• Open-market sale: 11,430 shares @ weighted avg $123.58 = $1,412,519 (sales executed at prices between $123.51 and $123.62).
• Net proceeds before taxes/fees ≈ $1.26M (proceeds minus exercise cost).
• Shares owned following the transactions: not specified in the provided excerpt of the Form 4.
• Footnotes: F1 — transactions were made pursuant to a Rule 10b5-1 trading plan (adopted Dec 23, 2025). F2 — sale price is a weighted average across multiple trades; detailed per-trade prices available on request. F3 — the optioned shares were fully vested.

Context

• This was an option exercise followed by an immediate sale (a common way to cover exercise costs and taxes); the 10b5-1 plan indicates the sale was pre-arranged. The filing is informational and does not, by itself, indicate the insider’s view of the company’s prospects.